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Objectives. To assess whether electrical stimulation of ischaemic calf muscles in claudicants causes a systemic
inflammatory response and to evaluate effects of its chronic application on muscle function and walking ability.
Design. Prospective randomised controlled trial of calf muscle stimulation.
Materials and methods. Stable claudicants were randomised to receive either active chronic low frequency (6 Hz) motor
stimulation (n ¼ 15) or, as a control treatment, submotor transcutaneous electrical nerve (TENS) stimulation (n ¼ 15) of
calf muscles in one leg, 3 £ 20 min per day for four weeks. Leucocyte activation was quantified by changes in cell
morphology, vascular permeability by urinary albumin:creatinine ratio (ACR), calf muscle function by isometric twitch
contractions and walking ability by treadmill performance pre- and post-intervention.
Results. Acute active muscle stimulation activated leucocytes less (28% increase) than a standard treadmill test (81%
increase) and did not increase ACR. Chronic calf muscle stimulation significantly increased pain-free walking distance by
35 m (95% CI 17, 52, P , 0.001) and maximum walking distance by 39 m (95% CI 7, 70, P , 0.05) while control
treatment had no effect. Active stimulation prevented fatigue of calf muscles during isometric electrically evoked
contractions by abolishing the slowing of relaxation that was responsible for loss of force.
Conclusions. Chronic electrical muscle stimulation is an effective treatment for alleviating intermittent claudication which,
by targeted activation of a small muscle mass, does not engender a significant systemic inflammatory response.
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Introduction
In patients with peripheral vascular disease (PVD) and
intermittent claudication, leg muscles display changes
characteristic not only of chronic ischaemia, but also of
muscle disuse, which develops as pain on walking
limits exercise capacity. These changes include
impaired aerobic energy production,1 decreased oxi-
dative enzyme capacity and a shift towards less
oxidative Type II muscle fibres2 – 4 and fibre atrophy.5
Exercise training of PVD patients is well known to
alleviate some of these alterations by elevating activity
of oxidative enzymes and improving aerobic metab-
olism and oxygen extraction, all of which are linked
with significant increases in walking performance and
hence functional status.6 – 8
Chronic low frequency electrical stimulation
(CLFES) of fast muscles can mimic many of the effects
of endurance exercise. In healthy animal muscles, it
rapidly elevates oxidative enzyme capacity and
capillary supply, thereby improving fatigue resist-
ance.9 Human muscle, although less amenable to the
transforming effects of CLFES, can show similar
responses. Stimulation of healthy human quadriceps
for 6–8 weeks elevated levels of oxidative enzymes,
increased capillarity around fast fibres, and improved
resistance to fatigue.10,11 On the basis of studies12
showing that CLFES enhanced capillary supply and
blood flow and reduced fatigue in chronically ischae-
mic rat muscles, Tsang et al.13 stimulated the anterior
and posterior tibial muscles of claudicants at a low
frequency for short periods each day for four weeks.
Muscle performance tested by measuring ankle dorsi-
flexor fatigue was improved after stimulation and
maximum and pain-free walking distances were
significantly greater.
For claudicants, one potential disadvantage of
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training using whole body exercise such as walking or
cycling is that the ischaemic muscles experience
repeated episodes of inadequate flow followed by
reperfusion on cessation of exercise. These may
engender a repetitive low-grade inflammatory
response involving neutrophil activation14 – 17 that
can lead to a systemic increase in vascular per-
meability18,19 and may be associated with the
increased risk of cardiovascular events and mortality
in this patient group.8 CLFES offers an alternate means
of exercising muscles in a targeted manner in
comparison with whole body training, but is not
known if it induces neutrophil activation in PVD
patients which could increase cardiovascular risk.
The present study was therefore carried out to
investigate leucocyte activation in response to calf
muscle stimulation in patients with intermittent
claudication, and to see whether application of muscle
stimulation on a chronic basis could improve walking
ability and calf muscle function as endpoints without
adverse effects on leucocytes. The large muscle group
of the calf was chosen for treatment because it
comprises the major synergists for plantar flexion,
plays a prominent role in walking, and is the common
site of ischaemic pain limiting exercise performance.
Method
Patient population
With approval from South Birmingham Local
Research Ethics Committee, 30 patient volunteers
were recruited over a period of 18 months from
those attending the Vascular Assessment Clinic at
University Hospital Trust, Selly Oak, Birmingham.
Patients were included in the single blind study if they
had stable claudication for 3 months or longer, had a
post-exercise ankle-brachial pressure index (ABPI) of
,0.8 and were able to walk between 50 and 350 m on a
standard treadmill test.
Study protocol
Patients attended the laboratory at the hospital for five
visits at fortnightly intervals, the first of these being an
habituation session the data from which was excluded
from final analysis. At the second visit, patients were
assessed by treadmill to determine claudication and
maximal walking distances, and supine resting and
post-exercise ABPIs. Calf muscle function of the worse
affected leg was objectively evaluated by measuring
fatigue during a test of electrically evoked isometric
contractions. Blood samples from an antecubital vein
and mid-stream urine specimens were collected before
and 1 h after completion of the muscle function test.
Patients were then randomly assigned, 15 in each
group, to receive four weeks of either active CLFES
treatment or control treatment, the latter provided by
transcutaneous electrical nerve stimulation (TENS)
machines (see below). They returned after two weeks
for a muscle function test only, and after four weeks,
all tests (treadmill, ABPIs, muscle function, blood and
urine sampling) were performed as final outcome
measures. Two weeks after cessation of treatment, a
test of muscle function was performed to evaluate the
persistence of any CLFES effects.
Testing procedures
Treadmill performance and ABPI
After 1 h of rest, ABPIs were measured in the supine
position immediately before and after a standardised
maximum walking test performed on a Powerjog E10
treadmill (Sport Engineering Ltd., UK), 10% incline at
a speed of 2.5 km h21. Claudication distance was
defined by the initial onset of claudicating pain and
maximum walking distance by that achieved before
pain became too severe to continue.
Calf muscle function
Calf muscle function was tested during 5 min of
electrically-evoked twitch contractions. Patients were
seated in a custom-made chair with the lower leg
under investigation fixed by a knee clamp and the foot
resting on a plate to which strain gauges were attached
for measurement of isometric plantar flexion torque.20
Calf muscles were contracted at frequencies of 3.5–
5 Hz by transcutaneous electrical motor stimulation
(pulse duration 50 ms, 100 V) using a Devices DS7
constant voltage stimulator (Devices Instruments,
Welwyn Garden City, UK) controlled through a
MacLab 4e system (ADInstruments Ltd., Hastings,
UK). To avoid high contraction forces that would not
be tolerable for ischaemic muscles in the patients,
initial torque was set by adjusting stimulus intensity to
produce about half the value used in healthy sub-
jects,20 i.e. as close to 7.5 Nm as possible. Muscle
torque was recorded throughout 5 min stimulation at a
frequency which gave repeated unfused twitch
contractions.
Torque was averaged from 5 twitches every 10 s
throughout the test and muscle function was assessed
as torque measured 10 s prior to the end of the test as a
percentage of that measured 10 s after the start, to
avoid any movement artefacts. The time course of
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individual twitch contractions was evaluated by
expanding recordings taken throughout the test and
measuring time to peak contraction (TTP) and time to
half relaxation (1/2RT).
Blood and urine testing
To investigate whether muscle electrical stimulation
had any effect on systemic leucocyte activation, mixed
venous blood samples and urine specimens were
taken before and 1 h after the calf muscle function
testing and the treadmill test. Blood was collected into
EDTA tubes and processed immediately after collec-
tion to extract leucocytes according to the method
described by McCarthy et al.21 Briefly, 1 ml samples
were fixed with paraformaldehyde, lysed and centri-
fuged to remove red cells and platelets to yield a
suspension of leucocytes which were then stained
with Toluidine blue. The external morphology of cells
was examined by light microscopy ( £ 400) and the
proportion of activated cells (ruffled or irregular
surface appearance) as opposed to quiescent cells
(smooth round surface) was determined in the whole
sample.21,22
Urine samples were stored with sodium azide at
4 8C until microalbuminurea could be determined by
standard radioimmunoassay (Double Antibody Albu-
min, Euro/D.P.C. Ltd., UK). Creatinine content was
also estimated (kit from Synermed Europe Ltd., UK) so
that urinary albumin:creatinine ratio (ACR) could be
calculated.18
Chronic calf muscle stimulation
Treatment, carried out by patients at home, was
applied unilaterally to the calf muscle of the leg
which had the lowest ABPI values on baseline testing.
Active CLFES treatment involved using Compex
stimulators (MediCompex SA, Ecublens, Switzerland)
programmed to deliver square wave pulses (250 ms
duration, 100 V) at a frequency of 6 Hz for 20 min
periods. Patients were instructed in placement of
electrodes over the motor point and belly of triceps
surae and in adjusting stimulation intensity to
produce visible pain-free calf muscle contractions.
They used the stimulators three times per day with an
interval of at least 2 h between sessions, usage being
registered by the stimulator programme card. Control
treatment involved using TENS machines (SKF Ser-
vices Ltd., Kent, UK) which were set to deliver an
output at 50 ms, 100 V and 90 Hz. Patients were again
instructed in positioning of electrodes and were asked
to increase stimulus intensity until a perceived
sensation of tingling without muscle contraction was
obtained, and perform three sessions each of 20 min
duration per day. TENS machines were used as a
placebo treatment that did not induce active muscle
contraction.
Statistical analysis
Comparisons of blood and urine data were made
within active or control treatment groups by Wilcoxon
signed rank test and between patient treatment groups
by Mann–Whitney U tests for non-parametrically
distributed data, which is, therefore, presented in the
results as median (interquartile range (IQR)). Analysis
of variance (ANOVA) with Scheffe’s post hoc tests was
performed on parametric treadmill, muscle function
and ABPI data where two or more samples were
compared. These data are presented as means (stan-
dard deviations (SD)). Analyses were performed using
Statview software (Abacus Concepts, USA) with
significance in all cases set at the 5% level.
Results
There were no significant differences in baseline
descriptors of the patients assigned to active or control
treatment groups (Table 1). The most common site of
the limiting occlusion was the popliteal artery in 10 of
the active group and nine of the control group, the
remaining occlusions located in the femoral (active 1,
control 2) or tibial (active 4, control 3) arteries. Mean
(SD) ankle-brachial pressure indices in the worst
affected leg, 0.64(0.14) for all patients, classed them
as having mild claudication and following treadmill
exercise, ABPIs decreased on average by 30(51)%
ðP , 0:005Þ. Baseline claudication and maximum
walking distances were similar for the groups
(Table 1), with the total duration of treadmill exercise
not exceeding 3 min.
Significant improvements in treadmill performance
were observed after chronic muscle stimulation
(Table 2). After active treatment, claudicating and
maximum walking distances were 93(37) and
150(63) metres, respectively, increases of 82(108)%
ðP , 0:01Þ and 44(50)% ðP , 0:05Þ from baseline. By
contrast, patients receiving the control treatment
showed no significant change from baseline in either
claudicating (64(38) m, NS) or maximum walking
(114(100) m, NS) distances. After CLFES, the improve-
ments in pain-free walking were more marked in
seven patients with unilateral disease in whom
treatment was targeted at the affected leg (distance
increased 102(155)%) than in the remaining eight with
bilateral disease where treatment was only applied to
the worse affected leg (increase of 64(42)%). Better
walking ability in the active group was not related to
changes in ABPIs, since values in the treated leg were
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not different at rest nor was the fall post-treadmill
exercise altered (0.60(0.13) and 36(29)%, respectively,
NS vs. baseline testing).
Fig. 1(A) shows a typical example of torque
recording during the calf muscle function test from
one patient at baseline. At the start of the baseline test
torque was 7.2(0.9) Nm in the active group and
7.4(1.4) Nm in the control group. Six patients were
unable to complete the full 5 min test, one ceasing after
1 minute, one after 2 minutes and four between 4 and
5 min. For all other patients who completed the
baseline test, twitch torque had declined to 73(30)%
of initial values by 5 min because the muscles
progressively fatigued. They were unable to relax
quickly enough to generate single twitches, and
contractions became partially fused such that basal
torque had risen above zero by 80–90 s into the test
(Figs. 1(A) and 2(A)). The changes in contraction times
underlying this effect were a prolongation of half
relaxation time from 78(16) ms at the start of the test to
159(133) ms at the end ðP , 0:01Þ, whereas times to
peak contraction were unaltered (86(14) ms at the start,
84(22) ms at the end, NS).
All patients who received active CLFES treatment
for 4 weeks were able to complete the full 5 min
muscle function test. After two weeks, the marked
slowing of relaxation time and rise in basal torque
during the electrically evoked contractions were less
(Fig. 2(B)) and after four weeks, they no longer
occurred (Figs. 1(B) and 2(C)). There was no twitch
fusion and in consequence, force was maintained
throughout the test. By contrast, muscle function in
patients receiving the control TENS stimulation
showed the same slowing and fatigue as they had at
baseline testing (Fig. 2(D)). When patients who had
received active treatment were tested two weeks after
its cessation, muscle force traces showed a reversion to
the baseline pattern (data not shown).
At baseline testing, median (IQR) values for
morphological signs of cell activation under resting
conditions were 10.5(9.7 – 12.8)% of leucocytes
sampled from all patients and this increased to
13.9(12.5–15.6)% in blood taken 1 h after electrical
stimulation for the calf function test (P , 0:001, Fig. 3).
Cell activation was, however, even greater in samples
taken 1 h after a treadmill test where the proportion
of activated leucocytes was 18.5(16.3–19.6)% ðP ,
0:001Þ even though the duration of treadmill
exercise (,3 min) was shorter than that of the
chair test (4–5 min) (Fig. 3). Urinary ACRs were
1.27(0.63–3.77) mg mmol21 before and 1.38(0.55–
2.78) mg mmol21 after calf muscle testing (NS) show-
ing that acute stimulation did not cause any change in
systemic microvascular permeability. Ratios were
higher after the treadmill than the chair test
(3.85(1.09–8.68) mg mmol21) but the increase was
not significant due to large inter-subject variation.
After chronic active stimulation for 4 weeks, the
proportion of activated leucocytes at rest (10.1(8.5–
11.2)%) was not different from baseline and the
Table 1. Patient descriptors for active and control treatment groups at the start of the study. Data are given as means (standard deviations).
Ranges are given in parentheses below where appropriate.
Active treatment Control treatment
Number 15 15
Age in years 66(6) 71(5)
(53–80) (61–80)
Male:female ratio 2:1 4:1
Current smokers 2 2
Duration of symptoms in years 4.9(3.9) 5.1(4.8)
(1–15) (0.5–20)
Ankle-brachial pressure index at rest 0.64(0.10) 0.63(0.18)
Claudicating distances in metres 58(28) 64(37)
Maximum walking distance in metres 111(42) 115(82)
Table 2. The effects of 4 weeks of chronic calf muscle motor stimulation (active treatment) versus sub-motor TENS stimulation (control
treatment) on treadmill performance.
Active treatment Control treatment
Change in claudicating distances in metres þ35(31)* 20.1(5)
(CI þ17, þ52) (CI 23, þ3)
Change in maximum walking distance in metres þ39(57)** 21(27)
(CI þ7, þ70) (CI 217, þ15)
Data are given as means (standard deviations) with 95% confidence intervals. *P , 0:001, **P , 0:05 active vs. control treatments.
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increase following a treadmill test (17.3(16.4–19.0)%)
was also unchanged. Urinary ACRs were not signifi-
cantly altered at rest (0.60(0.42–6.21) mg mmol21) or
in response to treadmill exercise (2.61(1.20 –
10.47) mg mmol21).
Discussion
This study shows that low frequency electrical
stimulation of calf muscles in PVD patients has
minimal effects on leucocyte activation, assessed by
Fig. 1. Records of electrically-evoked isometric torque (Nm) developed during the test of calf muscle function from one
patient pre (A) and post (B) 4 weeks CLFES. At baseline testing (A), the force of individual twitch contractions declined after
2 min due to slowing of the twitch relaxation and failure of the muscle to relax to zero torque (see inset figures, bar ¼ 1 s).
This no longer happened after CLFES. Any torque shown below zero represents dorsi-flexion rather than plantar flexion,
usually due to small adjustments in body position by the patient.
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their morphology, and does not influence systemic
vascular permeability when applied acutely, nor did it
have any deleterious consequences for leucocyte
activation or systemic microvascular permeability
when used as a chronic treatment. CLFES was,
however, highly effective at inducing improvements
in functional walking capacity of patients.
Enhancement of walking was particularly evident
in cases of unilateral disease where the affected leg
had been specifically targeted by stimulation and
its hindrance to walking performance thereby
ameliorated.
These positive effects of calf muscle stimulation
confirm the findings of Tsang et al.13 who stimulated
anterior tibial muscles for four weeks, but the
improvement in pain-free walking was even greater,
82% compared with 26%. This is likely because
treatment was applied to the larger triceps surae
muscle group which makes a more prominent
contribution during the gait cycle.23 The local nature
of the treatment effect is shown by the fact that
maximum walking distances, which would be cur-
tailed by the untreated leg as well as being influenced
by cardiorespiratory and motivational limitations,
increased similarity in the two studies (44 and 34%
respectively). Only one other study has reported
positive effects of gastrocnemius muscle electrical
stimulation in patients with PVD, using it in conjunc-
tion with an exercise training programme applied to
the leg remaining after amputation.24 It reported that
claudication was alleviated by stimulation combined
Fig. 2. Panels show grouped data for average peak and base torque values for 5 twitch contractions measured every 10 s
during the chair test. (A) For all patients pre treatment, (B) for patients receiving active stimulation after 2 weeks, (C) for
patients receiving active treatment after 4 weeks, (D) for patients receiving 4 weeks of control treatment (D).
Fig. 3. Percentage of activated leucocytes, assessed by
morphological cell shape change, in venous blood taken
1 h after either acute calf muscle stimulation (max 5 min) or
treadmill exercise (max 3 min) from all claudicants pre-
treatment. †p , 0:001 versus rest, paired t-test.
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with exercise but not by exercise alone but the
stimulation protocol was more intensive, 2 h per day
over 8 weeks, than presently used and the effect of
stimulation per se was not evaluated.
Neutrophil activation in claudicants following
exercise17,25 is a consequence of ischaemia-reperfusion
and has been considered to present a significant risk
by contributing to the likelihood of their adherence to
vascular endothelium and to a generalised increase in
systemic vascular permeability15,16 which has been
shown in claudicants by urinary microalbuminuria.18,
19 In the present patient population, a single bout of
calf electrical stimulation lasting 4–5 min for the
muscle function test had significantly less effect on
leucocyte activation (28% increase) than did treadmill
walking for the shorter period of ,3 min (81%).
Neumann et al.25 observed that total neutrophil
numbers as well as the proportion of activated
neutrophils were significantly elevated in venous
blood leaving the legs compared to arterial blood
after toe raise exercise to claudication, indicating a
release of cells ‘washed out’ from the ischaemic limb
itself by post-exercise reperfusion. Calf stimulation at
submaximal intensity may involve a relatively small
proportion of the muscle group compared with leg
exercise so that any such reperfusion effects are minor.
Furthermore, the small increase in leucocyte activation
during stimulation did not induce systemic vascular
permeability, based on the lack of change in ACRs, in
contrast to the known effects of treadmill exercise. The
increase in ACRs after treadmill was not significant in
the present study most likely because of small patient
numbers.15 The local nature of electrically-evoked
muscle contractions in comparison with whole body
exercise therefore, means that CLFES as a treatment
does not pose any risk to patients of aggravating
inflammatory status, neither does it modulate the
leucocyte activation response to treadmill exercise. A
further possible benefit of CLFES is that a smaller
degree of leucocyte activation than during exercise
training would have less adverse effects on adhesion
molecule expression which is associated with endo-
thelial dysfunction in claudicants.26
The total treatment time with chronic stimulation
(20 min three times daily, 7 days per week, 4 weeks)
amounted to 28 h. Compliance was greater than 95%
in both active and control treatment groups, as
registered by stimulator cards or by self-report.
Although exercise training programmes may result
in greater improvements in pain-free and maximum
walking distances than the present study,7 the mini-
mum duration required, using sessions of 30 min up to
1 h which may be repeated daily or several times per
week, is of the order of 3–6 months.7,14 Set against this,
the magnitude of functional improvements in the
present study show self-administered chronic stimu-
lation to be a very effective treatment for claudicants.
CLFES can be carried out by patients themselves after
minimal tutoring in equipment use, and does not
require attendance at a supervised exercise class, the
usual recommendation for ensuring patient adherence
to a physical activity programme.
Stimulation could exert its beneficial effects on
walking ability by altering metabolic efficiency of the
targeted muscle. Fatigue during electrically evoked
twitch contractions in patients prior to treatment was
evident as an inability to regain baseline between
contractions due to slowing of muscle relaxation. This
differed from the response during the chair test of
healthy calf muscle with restricted blood flow in which
force production declined without any slowing of
contraction times.20 The contractile properties of calf
muscles in the patient group at baseline were
significantly faster than times to peak contraction
(,170 ms) and half relaxation (130 ms) reported for
plantar flexor muscles in healthy elderly individuals,27
consistent with the observed increase in fast myosin
heavy chains4 and change in fibre population towards
the fast type in ischaemic muscles of PVD patients.2,3
In fatigued muscle, slower relaxation has been
attributed to prolongation of the Ca2þ transient due
in part to the effect of elevated Hþ concentration on the
Ca2þ pump rate of the sarcoplasmic reticulum28 and
during calf exercise, muscle pH falls to a greater extent
in claudicants than healthy age-matched controls.1
Whether the elimination of slowing of relaxation in
treated muscles implies that CLFES had negated
metabolic inefficiency independently of any vascular
effects remains to be investigated.
With regard to the possibility that CLFES has
vascular effects, the fact that ankle-brachial pressure
indices for the stimulated leg were not changed by
CLFES either at rest or post-exercise would suggest
that overall perfusion had not been influenced, and
indeed, the majority of exercise training studies in
PVD patients also show that limb blood flow is not
enhanced.6 However, while ABPI measurements are
good at predicting the severity of arterial disease they
cannot discriminate redistribution of perfusion within
the ischaemic limb. Low frequency electrical stimu-
lation of anterior tibial muscles for several weeks in
PVD patients improved skin oxygen saturation and
led to healing of ulcers,29 which implies a cutaneous
vascular effect. In animals with stenosed arteries
supplying the lower limbs, exercise training led to
better walking performance which was not associated
with higher limb blood flow but was thought to be
linked with more homogeneous distribution of flow
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and better oxygen delivery among muscles.30 This
would necessitate alterations in the fine control of
arterial vessels that regulate perfusion through indi-
vidual muscle capillary beds. Disturbances of resist-
ance vessel control have been demonstrated in PVD
patients as reduced calf reactive hyperaemic responses
to thigh occlusion31 and depressed endothelial and
smooth muscle function in resistance arteries from
patients with critical limb ischaemia.32,33 Our own
work in a rat model of intermittent claudication (iliac
artery ligation) showed that impaired vasodilator
responses of the smallest arterioles in ischaemic limb
skeletal muscle is a very early feature,34 whereas
changes in fibre type or metabolism are not evident
even after several weeks.35,36 Furthermore, we have
evidence that CLES applied intermittently to ischae-
mic rat hindlimb muscles can restore dilator capacity
to these vessels,37 and can also enhance hyperaemia in
response to muscle contractions.12 A vascular effect of
stimulation that would optimise calf muscle perfusion
is, therefore, a possible contributory factor in the
improved walking ability of patients receiving the
active treatment in this study.
In conclusion, CLFES is a simple and effective
treatment for claudication that can be targeted to
affected muscles, and improves patient walking ability
without inducing a systemic inflammatory response.
As a therapeutic modality, it is uses simple resources,
involves little daily time and requires minimal super-
vision. The mechanism of action of stimulation on
ischaemic muscles is likely to be a combination of
enhanced oxygen delivery by restoration of vasodi-
lator capacity and improved metabolic efficiency.
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